Aggregation of Therapeutic Proteins
This book gives pharmaceutical scientists an up-to-date resource on protein aggregation and its consequences, and available methods to control or slow down the aggregation process. While significant progress has been made in the past decade, the current understanding of protein aggregation and its c...
Saved in:
| Main Authors | , |
|---|---|
| Format | eBook Book |
| Language | English |
| Published |
Hoboken, N.J
Wiley
2010
John Wiley & Sons, Incorporated Wiley-Blackwell |
| Edition | 1. Aufl. |
| Subjects | |
| Online Access | Get full text |
| ISBN | 0470411961 9780470411964 0470769815 9780470769812 0470769823 9780470769829 |
| DOI | 10.1002/9780470769829 |
Cover
Loading…
| Abstract | This book gives pharmaceutical scientists an up-to-date resource on protein aggregation and its consequences, and available methods to control or slow down the aggregation process. While significant progress has been made in the past decade, the current understanding of protein aggregation and its consequences is still immature. Prevention or even moderate inhibition of protein aggregation has been mostly experimental. The knowledge in this book can greatly help pharmaceutical scientists in the development of therapeutic proteins, and also instigate further scientific investigations in this area. This book fills such a need by providing an overview on the causes, consequences, characterization, and control of the aggregation of therapeutic proteins. |
|---|---|
| AbstractList | This book gives pharmaceutical scientists an up-to-date resource on protein aggregation and its consequences, and available methods to control or slow down the aggregation process. While significant progress has been made in the past decade, the current understanding of protein aggregation and its consequences is still immature. Prevention or even moderate inhibition of protein aggregation has been mostly experimental. The knowledge in this book can greatly help pharmaceutical scientists in the development of therapeutic proteins, and also instigate further scientific investigations in this area. This book fills such a need by providing an overview on the causes, consequences, characterization, and control of the aggregation of therapeutic proteins. While significant progress has been made in the past decade, the current understanding of protein aggregation and its consequences is still immature. Aggregation of Therapeutic Proteins provides an up-to-date resource on protein aggregation and its consequences, and available methods to control or slow down the aggregation process |
| Author | Wang, Wei Roberts, Christopher J |
| Author_xml | – sequence: 1 fullname: Wang, Wei – sequence: 2 fullname: Roberts, Christopher J |
| BackLink | https://cir.nii.ac.jp/crid/1130000796599048576$$DView record in CiNii |
| BookMark | eNqNkMtLAzEQxiM-0GqP3ouK4KE6k3eOWuoDCnoQxdOSbbPb4Lqpm63if2_qinr0MsMHv5n5vumRjTrUjpB9hFMEoGdGaeAKlDSamjXS_6ORrpPeSnBEI3GT9CikGdCc6i2yIyXlgiVym_Rj9DmAMUqgxB1yeF6WjStt60M9CMXgfu4au3DL1k8Hd01ona_jHtksbBVd_7vvkofL8f3oeji5vboZnU-GVoABNZTcsOQNc-mEnWlDteVcWWSa0YI6QFpAYbjSQuVKgDDa5lzmTs604tQKtktOusU2Prv3OA9VG7O3yuUhPMcs5UXElJkJ_Q_29zeJPe7YRRNely622Rc2dXXb2CobX4xE8i55Ao86sPY-m_pVRWTpkaCMFMYAT97l721fLpZ55ePc12W2aPyLbT6yx5vJ-OkCABmTK58HHTv1tp6FH6qTXGvUkn0C17SGdQ |
| ContentType | eBook Book |
| DBID | 08O WIIVT RYH |
| DEWEY | 615.5′8 |
| DOI | 10.1002/9780470769829 |
| DatabaseName | ciando eBooks Wiley CiNii Complete |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology Medicine |
| EISBN | 9780470769812 0470769815 9781118043585 1118043588 |
| Edition | 1. Aufl. 1st ed. 1 |
| ExternalDocumentID | 9781118043585 9780470769812 EBC564964 BB07438077 WILEYB0013365 ciando488186 |
| GroupedDBID | 089 08O 20A 38. 3VX 3X9 3XM 5VX 69Y A4J AABBV AARDG ABARN ABIAV ABQPQ ABQPW ACIQC ACLGV ADVEM AERYV AFOJC AHUFE AHWGJ AIMYK AJFER AKHYG ALMA_UNASSIGNED_HOLDINGS AZZ BBABE CZZ DNKAV GEOUK HF4 IFKZM IWG J-X JFSCD JJU KIGQS LQKAK MYL PQQKQ UZ6 W1A WIIVT YPLAZ ZEEST RYH AHCZW IVK |
| ID | FETCH-LOGICAL-a50907-64939821b6e5ad8928a447a13832f2e012f0f947857b750598ab46be6d8742a53 |
| ISBN | 0470411961 9780470411964 0470769815 9780470769812 0470769823 9780470769829 |
| IngestDate | Fri Nov 08 04:11:37 EST 2024 Thu Feb 27 10:06:20 EST 2025 Wed Sep 03 01:53:53 EDT 2025 Fri Jun 27 00:27:04 EDT 2025 Fri Aug 29 02:53:43 EDT 2025 Fri Aug 15 18:57:51 EDT 2025 |
| IsPeerReviewed | false |
| IsScholarly | false |
| Keywords | Gesundheit Sonstiges Medizin |
| LCCN | 2010008428 |
| LCCallNum | RS431.P75A34 |
| LCCallNum_Ident | RS431.P75A34 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-a50907-64939821b6e5ad8928a447a13832f2e012f0f947857b750598ab46be6d8742a53 |
| Notes | Includes bibliographical references and index |
| OCLC | 662453076 |
| PQID | EBC564964 |
| PageCount | 515 |
| ParticipantIDs | askewsholts_vlebooks_9781118043585 askewsholts_vlebooks_9780470769812 proquest_ebookcentral_EBC564964 nii_cinii_1130000796599048576 igpublishing_primary_WILEYB0013365 ciando_primary_ciando488186 |
| ProviderPackageCode | J-X |
| PublicationCentury | 2000 |
| PublicationDate | 2010 2010. c2010 2010-07-13 2010-12-28 |
| PublicationDateYYYYMMDD | 2010-01-01 2010-07-13 2010-12-28 |
| PublicationDate_xml | – year: 2010 text: 2010 |
| PublicationDecade | 2010 |
| PublicationPlace | Hoboken, N.J |
| PublicationPlace_xml | – name: Hoboken, N.J – name: Newark |
| PublicationYear | 2010 |
| Publisher | Wiley John Wiley & Sons, Incorporated Wiley-Blackwell |
| Publisher_xml | – name: Wiley – name: John Wiley & Sons, Incorporated – name: Wiley-Blackwell |
| SSID | ssib009975161 ssj0000411457 ssib017658513 |
| Score | 2.283767 |
| Snippet | This book gives pharmaceutical scientists an up-to-date resource on protein aggregation and its consequences, and available methods to control or slow down the... While significant progress has been made in the past decade, the current understanding of protein aggregation and its consequences is still immature.... |
| SourceID | askewsholts proquest nii igpublishing ciando |
| SourceType | Aggregation Database Publisher |
| SubjectTerms | Aggregation (Chemistry) Cell Aggregation Development Drug Discovery MEDICAL Pharmacology Protein Conformation Protein drugs Protein Folding Recombinant Proteins -- metabolism Recombinant Proteins -- therapeutic use |
| SubjectTermsDisplay | Development Drug Discovery MEDICAL Pharmacology |
| TableOfContents | AGGREGATION OF THERAPEUTIC PROTEINS -- CONTENTS -- PREFACE -- CONTRIBUTORS -- CHAPTER 1: Fundamental Structures and Behaviors of Proteins -- 1.1 THE PROBLEM OF PROTEIN AGGREGATION -- 1.1.1 Structural Features of Proteins -- 1.1.2 Structural Features of Protein Aggregates -- 1.2 PARALLELS TO PROTEIN FOLDING -- 1.3 VIEWS OF PROTEIN STABILITY AND AGGREGATION -- 1.3.1 Physicochemical Properties of Proteins -- 1.3.2 Surface Properties and Packing Arrangements -- 1.3.3 Solvent Interactions -- 1.4 MODELS OF AGGREGATION -- 1.4.1 Monomer Conversion -- 1.4.2 Oligomeric Intermediates -- 1.4.3 Nucleation in Protein Folding -- 1.4.4 Domain Swapping -- 1.5 MODELS OF PROTEIN FOLDING -- 1.5.1 Classical Models Based on Chemical Equilibrium -- 1.5.2 Statistical Mechanical Models -- 1.5.3 Computational Models -- 1.5.4 Application of Coarse-Grained Models -- 1.5.5 Information Theory (IT) -- 1.6 INFLUENCES OF CHEMICAL ALTERATION ON AGGREGATION -- 1.6.1 Length of the Polypeptide Chain -- 1.6.2 Methionine Oxidation -- 1.6.3 Covalent Cross-Linking of Strands -- 1.6.4 Deamidation -- 1.6.5 Proline Isomerization -- 1.7 APPROACHES TO PREDICTING AGGREGATION -- 1.8 CONCLUSIONS -- REFERENCES -- CHAPTER 2: Protein Aggregation Pathways, Kinetics, and Thermodynamics -- 2.1 INTRODUCTION -- 2.2 NATIVE AND NONNATIVE AGGREGATION PATHWAYS -- 2.3 THERMODYNAMICS OF REVERSIBLE SELF-ASSOCIATION -- 2.3.1 Self-Association of Folded/Native Proteins -- 2.3.2 Nonnative Self-Association -- 2.4 AGGREGATION KINETICS AND DISTINGUISHING KINETIC PATHWAYS -- 2.4.1 Aggregation Kinetics -- 2.4.2 Distinguishing Aggregation Pathways and Rate-Limiting Steps -- 2.4.3 Influence of Adsorption to Macroscopic Surfaces -- 2.5 CHEMICAL MODIFICATIONS -- 2.6 EFFECTS OF COSOLVENTS OR COSOLUTES -- 2.6.1 Transfer Free Energies and Preferential Interaction Parameters -- 2.6.2 Relating G32 to Molecular Interactions 2.6.3 An Additive Approach to Δμ2tr, ∂μ2 ∂ 3ex m , and G32(m3) -- 2.6.4 Predicting Cosolvent/Cosolute Effects on Unfolding, Association, and Aggregation -- APPENDIX-DERIVATION OF Γ32 FOR VAN DER WAALS (vdW) MIXTURE -- ACKNOWLEDGMENTS -- REFERENCES -- CHAPTER 3: Identification and Impact of Aggregation-Prone Regions in Proteins and Therapeutic Monoclonal Antibodies -- 3.1 INTRODUCTION -- 3.2 ENERGY LANDSCAPES, PROTEIN FOLDING, AND AGGREGATION -- 3.3 PREDICTION OF APRs IN PROTEINS AND BIOTHERAPEUTICS -- 3.3.1 Computational Tools -- 3.3.2 Experimentally Studied Aggregation-Prone Sequences and Sequence Patterns -- 3.3.3 Prediction of APRs in Therapeutic mAbs -- 3.3.4 Other Useful Studies -- 3.4 CONCLUSIONS AND FUTURE DIRECTIONS -- ACKNOWLEDGMENTS -- REFERENCES -- CHAPTER 4: External Factors Affecting Protein Aggregation -- 4.1 INTRODUCTION -- 4.2 PROTEIN AGGREGATION PATHWAYS -- 4.2.1 Physical Aggregation through Formation of Unfolding Intermediates -- 4.2.2 Direct Aggregation through Self-Association or Chemical Linkages -- 4.2.3 Indirect Aggregation through Chemical Degradation -- 4.2.4 Protein Aggregation from the Unfolded State -- 4.2.5 Aggregation Nucleation -- 4.2.6 Multiplicity in Protein Aggregation -- 4.3 EFFECTS OF TEMPERATURE -- 4.3.1 Relationship between Temperature and Protein Stability -- 4.3.2 Effect of High Temperature on Protein Aggregation -- 4.3.3 Melting Temperature (Tm) and Protein Aggregation -- 4.3.4 Effects of Low Temperature -- 4.4 EFFECTS OF SOLUTION CONDITIONS AND COMPOSITION ON PROTEIN AGGREGATION -- 4.4.1 Solution pH -- 4.4.2 Type and Concentration of Buffering Agents -- 4.4.3 Ionic Strength -- 4.4.4 Excipients/Additives -- 4.4.5 Protein Concentration -- 4.4.6 Metal Ions -- 4.4.7 Denaturant and Reducing Agents -- 4.4.8 Impurities -- 4.4.9 Organic Solvents -- 4.4.10 Containers/Closures -- 4.4.11 Sources of Proteins 9.5 CASE STUDIES 4 AND 5: AGGREGATION IN THE LYOPHILIZED STATE: ROLE OF RESIDUAL MOISTURE AND MECHANISMS OF EXCIPIENT STABILIZATION47,48 7.5.5 Subvisible Particle Acceptance Criteria -- 7.5.6 Visual Inspection Requirements -- 7.5.7 Visual Inspection Methods -- 7.5.8 What Does "Visible" Mean? -- 7.5.9 Potential Causes of Particulate Contamination in Parenteral Products -- 7.6 SUMMARY AND OUTLOOK -- REFERENCES -- CHAPTER 8: Approaches to Managing Protein Aggregation in Product Development -- 8.1 INTRODUCTION -- 8.2 APPROACHES IN FORMULATION DEVELOPMENT -- 8.2.1 Traditional Formulation Development -- 8.2.2 High-Throughput Formulation Development (HTFD) -- 8.2.3 Computer-Assisted Design of Formulations -- 8.3 PROTECTION OF PROTEINS IN VARIOUS PROCESSING STEPS -- 8.3.1 Shaking -- 8.3.2 Freezing/Thawing -- 8.3.3 Manufacturing Processes for Liquid Drug Product -- 8.3.4 Drying -- 8.3.5 Reconstitution -- 8.3.6 Preparation of Controlled Protein Delivery Systems -- 8.3.7 Miscellaneous Processes -- 8.4 AGGREGATION CONTROL BY STRUCTURAL MODIFICATIONS -- 8.4.1 Mutagenesis -- 8.4.2 PEG ylation -- 8.4.3 Glycosylation -- 8.5 SUMMARY -- REFERENCES -- CHAPTER 9: Case Studies Involving Protein Aggregation -- 9.1 INTRODUCTION -- 9.2 CASE STUDY 1: AGGREGATION IN THE LIQUID STATE: THE ROLE OF OSMOLYTES IN STABILIZING KGF TOWARD AGGREGATION -- 9.2.1 Background -- 9.2.2 Model Protein and Conditions -- 9.2.3 Results and Interpretation -- 9.2.4 Discussion and Lessons Learned -- 9.3 CASE STUDY 2: AGGREGATION IN THE LIQUID STATE: HETEROGENEITY AND NON-LINEARITY IN IgG2 AGGREGATION DURING LONG-TERM STORAGE35 -- 9.3.1 Background -- 9.3.2 Model Protein and Conditions -- 9.3.3 Results and Interpretation -- 9.3.4 Discussion and Lessons Learned -- 9.4 CASE STUDY 3: AGGREGATION IN THE FROZEN STATE: THE ROLE OF EXCIPIENT CRYSTALLIZATION42 -- 9.4.1 Background -- 9.4.2 Model Protein and Conditions -- 9.4.3 Results and Interpretation -- 9.4.4 Discussion and Lessons Learned 4.4.12 Light -- 4.5 EFFECTS OF PROCESSING STEPS ON PROTEIN AGGREGATION -- 4.5.1 Fermentation/Expression -- 4.5.2 Unfolding/Refolding -- 4.5.3 Purification -- 4.5.4 Freeze-Thaw -- 4.5.5 Agitation -- 4.5.6 High Hydrostatic Pressure -- 4.5.7 Drying -- 4.5.8 Preparation of Protein Delivery Systems -- 4.5.9 Analytical Methodologies -- 4.5.10 Miscellaneous Processes -- 4.6 EFFECTS OF SOLID-STATE CONDITION AND COMPOSITION ON PROTEIN AGGREGATION -- 4.6.1 Solid-State "pH" -- 4.6.2 Excipients and Excipient Levels -- 4.6.3 Physical State of the Solid -- 4.6.4 Moisture Content -- 4.7 SUMMARY -- ACKNOWLEDGMENT -- REFERENCES -- CHAPTER 5: Experimental Detection and Characterization of Protein Aggregates -- 5.1 INTRODUCTION -- 5.2 AGGREGATE CLASSIFICATION -- 5.2.1 Aggregate Nomenclature -- 5.3 ANALYTICAL TOOLS FOR THE CHARACTERIZATION OF AGGREGATES -- 5.3.1 SEC -- 5.3.2 Light Scattering -- 5.3.3 Analytical Ultracentrifugation (AUC) -- 5.3.4 FFF -- 5.3.5 Electrophoresis -- 5.3.6 Turbidimetry and Nephelometry -- 5.3.7 Analytical Techniques for Subvisible Particles -- 5.3.8 Visible Particles -- 5.3.9 Miscellaneous Technologies for Characterization of Protein Aggregates -- 5.3.10 Protein Structural Characterization in Aggregates: Spectroscopy-Based Techniques -- 5.4 SUMMARY -- REFERENCES -- CHAPTER 6: Approaches to Control Protein Aggregation during Bulk Production -- 6.1 INTRODUCTION -- 6.2 CANDIDATE SELECTION -- 6.2.1 Sequence Analysis -- 6.2.2 Stability to Process Conditions -- 6.2.3 Focus on Stability to Formulation and Long-Term Storage Conditions -- 6.2.4 Specific Considerations for Mammalian Cell Culture-Derived Protein -- 6.2.5 Specific Considerations for Bacteria-Derived Protein -- 6.3 PROTEIN AGGREGATION AND CELL CULTURE -- 6.3.1 Expression Strategies -- 6.3.2 Bioreactor Conditions -- 6.4 PROTEIN AGGREGATION AND PURIFICATION 6.4.1 Preventing Aggregation with Appropriate Solvent Conditions -- 6.4.2 Removal of Aggregates during Processing -- 6.4.3 Specific Considerations for Mammalian Cell-Derived Protein -- 6.4.4 Specific Considerations for Bacterial-Derived Proteins -- 6.4.5 Bulk DS Stability and Storage -- 6.4.6 Scale-Up -- 6.5 SUMMARY -- REFERENCES -- CHAPTER 7: Protein Aggregation and Particle Formation: Effects of Formulation, Interfaces, and Drug Product Manufacturing Operations -- 7.1 INTRODUCTION -- 7.2 ROLES OF CONFORMATIONAL AND COLLOIDAL STABILITY IN REDUCING RATES OF AGGREGATION -- 7.2.1 Conformational Stability -- 7.2.2 Colloidal Stability -- 7.3 EFFECTS OF INTERFACES ON PROTEIN AGGREGATION -- 7.3.1 Effects of Air-Water Interface -- 7.3.2 Protein Aggregation at Solid-Liquid Interfaces -- 7.3.3 Effects of Excipients on Structural Perturbation and Aggregation at Surfaces -- 7.3.4 Interactions of Proteins with Microparticle Surfaces -- 7.3.5 Protein Aggregation at Silicone Oil/Water Interfaces -- 7.3.6 Shear Effects on Protein Aggregation -- 7.4 CRITICAL PROCESSING STEPS DURING DRUG PRODUCT MANUFACTURING OF BIOPHARMACEUTICALS -- 7.4.1 Freezing and Thawing Operations -- 7.4.2 Mixing of Bulk Drug Solution after Thawing or Pooling -- 7.4.3 Preparation of Final Formulation with Excipients -- 7.4.4 Filtration -- 7.4.5 Filling -- 7.5 PARTICLES IN PARENTERAL PRODUCTS AND VISIBLE INSPECTION -- 7.5.1 Introduction: Understanding of Particles from the Parenteral Product Viewpoint is Important for Protein Biopharmaceutical Developers -- 7.5.2 The History of Visible Inspection and Particle Contamination Control in Parenteral Products -- 7.5.3 Current Regulatory Requirements on Particulate Contamination and Control of Subvisible and Visible Particles in Parenteral Products in the EU, United States, and Japan -- 7.5.4 Subvisible Particle Measurements |
| Title | Aggregation of Therapeutic Proteins |
| URI | http://ebooks.ciando.com/book/index.cfm/bok_id/488186 http://portal.igpublish.com/iglibrary/search/WILEYB0013365.html https://cir.nii.ac.jp/crid/1130000796599048576 https://ebookcentral.proquest.com/lib/[SITE_ID]/detail.action?docID=564964 https://www.vlebooks.com/vleweb/product/openreader?id=none&isbn=9780470769812&uid=none https://www.vlebooks.com/vleweb/product/openreader?id=none&isbn=9781118043585 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVYeWFPfIqyDSJAe9lS4sRfeW1VNCEN7aGwvUV261QVKJ1omTR-PceO81GYQPASNZHrG_lY1-de-54Q8tZyTa0xLKbai2ov5nGeWxNzXmZZZpwengsUzz-Ks0_swxW_6r6S5atLtmY0_3FnXcn_oIpnwNVVyf4Dsm2neIDfwBdXIIzrL-S3vQ1Hi5cIk5ct2-sVUZ144YVV1VLly5AQvrSrbnPFnaauARydTEaOZfoTND2lgSZDEBIC_lxZPyHgvclOlJgwmTDqlLfu9Jm1BmtoJ0WugoFdGerx2JENlUi5R_akhAO5j4Vzet4mtJwJxqWv-g_2aKNw1NgPIqew-G7H3j7Z15sv8Orw-NsNyIDL6CzWTj52ed2m47D8V6vVb4umZwKzh2TgqkMekXu2ekyOL2rh79vTaNZBsDmNjqOLThL89gl50wMsWpdRD7CoAewp-fx-OpucxeHzFLEGy0pkLFie4e2pEZjxC5WnSjMmNUXQn5apxdJfJmXOpOLSgJjxXGnDhLFioSRLNc-ekUG1ruxzEiUlwod5KksmBZPMGG1TW2qQSSsNGNaQvO4NUHHz1W-lb4reKNL0D42oU_oDM1Z8SA7qwS2uazmTor6FI6dKoIv-iLdtvMD72MULmUAXR8AB_3NX6vZDQTSdMGWO5QDx65C8ahAq_CuEc8bFdDzhGDTBXvylhwPyoJvZh2Sw_fbdHoH8bc3LMO1-Aux8S2Y |
| linkProvider | ProQuest Ebooks |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=book&rft.title=Aggregation+of+therapeutic+proteins&rft.au=Wang%2C+Wei&rft.au=Roberts%2C+J.+C.+%28John+Christopher%29&rft.date=2010-01-01&rft.pub=Wiley&rft.isbn=9780470411964&rft_id=info:doi/10.1002%2F9780470769829&rft.externalDocID=BB07438077 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fvle.dmmserver.com%2Fmedia%2F640%2F97804707%2F9780470769812.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fvle.dmmserver.com%2Fmedia%2F640%2F97811180%2F9781118043585.jpg |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fportal.igpublish.com%2Figlibrary%2Famazonbuffer%2FWILEYB0013365_null_0_320.png |